Fig. 7
From: GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer
GAD1 was proved to promote prostate cancer progression and modulate drug sensitivity in vivo. A Expression of GAD1 in prostate cancer cell lines predicted by the CCLE database. B Validation of GAD1 expression in prostate cancer cell lines. C, D Knock-down efficiency of GAD1, respectively LNCaP and PC3. GAD1clone tests in LNCaP (E) and PC3 (F). GAD1 scratch tests in LNCaP (G) and PC3 (H); right, wound healing assay, scale bar, 100 μm. GAD1 was proved to promote prostate cancer progression and modulate drug sensitivity in vivo. I GAD1 migration and invasion assay in LNCaP in 24-well plate; right, transwell assay, scale bar, 40 μm. J GAD1 migration and invasion assay in PC3 in 24-well plate. K GAD1 CCK8 assay in LNCaP; right, transwell assay, scale bar, 40 μm. L Effect of GAD1 on the enzalutamide IC50 in LNCaP in 24 h. M Effect of GAD1 on the docetaxel IC50 in LNCaP in 24 h. HPA database demonstrates differential expression of GAD1 in normal prostate tissue (N), high grade (O) and low grade (P) prostate cancer. Q Immunohistochemistry of cancer and paracancer in prostate cancer patients at our medical centres; right, immunohistochemistry, scale bar, 100 μm